Introduction
============

Hypertension is a major contributor to global disease burden, occurring as an insidious accompaniment to aging populations ([@b37]; [@b78]). It is estimated to have caused 7.1 million premature deaths in 2002 and is an ever-increasing worldwide problem ([@b78]). It is a well recognized risk factor for cardiovascular disease ([@b17]; [@b24]), and is often combined with other risk factors such as smoking, obesity, and physical inactivity ([@b78]), and it occurs commonly with diabetes ([@b1]).

Antihypertensive drugs are well known to prevent cardiovascular morbidity and mortality. The risks of stroke and myocardial infarction decrease by about 40% and 15%, respectively, in individuals who experience long-term diastolic blood pressure reduction of 5--6 mmHg ([@b20]). Hypertension management aims to reduce the long-term risk of cardiovascular complications, and involves lifestyle modifications, antihypertensive drug therapy, and treatment of comorbid conditions ([@b24]). The major antihypertensive drug classes (diuretics, calcium antagonists, β-blockers, angiotensin converting enzyme \[ACE\] inhibitors, and angiotensin receptor blockers) are all effective at lowering blood pressure, such that drug choice may be governed by patient characteristics (risk profile, concomitant disease), drug tolerability, cost of drugs, and the growing realization of the requirement for combination therapy to achieve goal blood pressure ([@b18]).

Calcium antagonists
===================

Calcium antagonists are a heterogeneous group of established antihypertensive agents that includes the phenylalkylamine, verapamil, the benzothiazepine, diltiazem, and the dihydropyridines (DHPs). The landmark series of prospective trials comparing calcium antagonists with other antihypertensive medications showed that, as a class, calcium antagonists produce similar effects to diuretics, β-blockers, and ACE inhibitors on cardiovascular mortality and combined morbidity, and that they reduce stroke in elderly hypertensive patients with isolated systolic hypertension (ISH) ([@b32], [@b31]; [@b12]; [@b2]).

The DHPs work primarily as vasodilators and have evolved from the first generation, short-acting compounds (eg, nifedipine and felodipine), which produced unwanted reflex tachycardia. Modified formulations were introduced to extend duration of action and limit adverse effects; however, amlodipine was the first DHP with an inherently long plasma half-life. The latest advance is the introduction of agents with a prolonged receptor half-life (reviewed in [@b46]) ([Figure 1](#fig1){ref-type="fig"}). The present review will describe the clinical efficacy and potential benefits of one of these newer agents, lercanidipine.

![Evolution of dihydropyridine calcium antagonists for improved clinical efficacy and tolerability. **Abbreviations:** GITS, gastrointestinal therapeutic system.](vhrm0103-173-f1){#fig1}

Pharmacology
============

Pharmacokinetics
----------------

Lercanidipine has a plasma half-life of 8--10 hours ([@b5]) but this does not relate to its duration of antihypertensive activity. Its high membrane partition coefficient provides a long-lasting effect at receptor and membrane levels ([@b33]) allowing for once-daily administration. Oral lercanidipine is maximally absorbed after 2 hours of administration, it exhibits high serum protein binding, and is rapidly accumulated in arteriolar cell membranes. It is metabolized by cytochrome P450 (CYP) 3A4 and the metabolites are eliminated in urine and feces ([@b5]). As with other DHPs, the potential for interaction with drugs that induce or inhibit P450 (CYP) 3A4 exists and should be considered (see review by [@b5]).

Pharmacodynamics
----------------

Preclinical studies show lercanidipine is highly selective for vascular tissue and produces smooth muscle relaxation through competitive binding to L-type calcium channels ([@b29]; [@b77]). It is highly lipophilic and is stored within cell membranes, which explains its slow onset of action and persistent smooth muscle relaxant effect ([@b29]; [@b70]; [@b33]). The antihypertensive effect of lercanidipine primarily occurs by peripheral and coronary vasodilatation ([@b71]). Lercanidipine has greater vascular selectivity and causes less negative inotropism in vitro than other DHPs including lacidipine, amlodipine, felodipine, and nitrendipine ([@b29]; [@b3]). It does not cause significant reflex tachycardia or other signs of sympathetic activation when given at therapeutic doses to patients with hypertension ([@b52]; [@b6]; [@b14]; [@b27]; [@b28]). Lercanidipine (10 mg/day) produces a smooth antihypertensive effect without unfavorable hemodynamic or sympathetic effects ([@b52]; [@b42]; [@b49]; [@b47]).

In addition to its general antihypertensive activity, lercanidipine has a nephroprotective effect in spontaneously hypertensive rats ([@b65]) and dilates both afferent and efferent arterioles ([@b63]; [@b64]). Lercanidipine may also have benefits in patients with hypertension and atherosclerotic disease where it is able to reside in cell membranes in the presence of high cholesterol levels ([@b33]). It has well described (in in vitro, animal, and clinical studies) antioxidant effects affecting vasodilatation and reducing oxidation of low-density lipoproteins ([@b10]; [@b23]; [@b35]; [@b56]; [@b73]; [@b74]). Regression of left ventricular hypertrophy has been described with lercanidipine in patients with hypertension, with or without diabetes ([@b25]; [@b69]). Interestingly, lercanidipine exerted a prolonged vasodilatory action in the microcirculation of 19 patients with hypertension, where it might protect against target organ damage ([@b15]).

Clinical studies
================

Efficacy in mild-to-moderate hypertension
-----------------------------------------

The efficacy of lercanidipine has been demonstrated in several uncontrolled trials (10--20 mg/day) carried out in more than 20 000 patients with mild-to-moderate hypertension ([@b9]; [@b68]; [@b30]; [@b58]; [@b41]). In summary, systolic and diastolic blood pressure reductions of 19--26 mmHg and 13--15 mmHg, respectively, were found 3--6 months after starting therapy.

There have been several comparisons of lercanidipine with other antihypertensive agents ([Table 1](#tbl1){ref-type="table"}). In double-blind/crossover studies, lercanidipine (10--20 mg/day) was as effective as amlodipine 10 mg/day ([@b22]; [@b53]), felodipine (10--20 mg/day) ([@b62]), and nifedipine slow-release (40--80 mg/day) ([@b54]) or gastrointestinal therapeutic system (GITS, 30--60 mg/day) formulations ([@b25]; [@b27]; [@b62]). Compared with other antihypertensive drugs, lercanidipine (10--20 mg/day) showed efficacy equivalent to atenolol (50--100 mg/day) ([@b48]), captopril (50--100 mg/day) ([@b66]), hydrochlorothiazide (12.5--25 mg/day) ([@b51]), losartan (50--100 mg/day) ([@b36]), telmisartan (80 mg/day) ([@b67]), and candesartan ([@b4]). In summary, lercanidipine reduced systolic and diastolic blood pressure in these studies, producing a high response rate and/or normalization of blood pressure in as little as 4 weeks of therapy ([Table 1](#tbl1){ref-type="table"}).

###### 

Efficacy and tolerability of lercanidipine compared with other antihypertensive drugs in patients with mild-to-moderate hypertension

  Study                                                   Study design/duration (w)                       N/Age (y)                                   Dosages (mg/day)   SBP/DBP at baseline (mmHg)   SBP/DBP at study end (mmHg)                          Responding (normalized) at 4 weeks (%)              Overall efficacy   Adverse events
  ------------------------------------------------------- ----------------------------------------------- ------------------------------------------- ------------------ ---------------------------- ---------------------------------------------------- --------------------------------------------------- ------------------ --------------------------------------------------------
  *Comparison with calcium antagonists*                                                                                                                                                                                                                                                                                           
  [@b53]                                                  sb, co/2                                        22/48 ± 5                                   L 20               L 146 ± 16/93 ± 13           L 138 ± 9/86 ± 9[a](#tf1-1){ref-type="table-fn"}     NR                                                  L≡A                L \< A (leg edema)[b](#tf1-2){ref-type="table-fn"}
                                                                                                                                                      A 10               A 148 ± 17/95 ± 11           A 137 ± 13/84 ± 9[a](#tf1-1){ref-type="table-fn"}                                                                           
  [@b22]                                                  db, co/4                                        20/55 ± 9[c](#tf1-3){ref-type="table-fn"}   L 20               L 162 ± 20/101 ± 5           L 141 ± 24/88 ± 10[d](#tf1-4){ref-type="table-fn"}   L 86 (86) (33)                                      L≡A                L≡A
                                                                                                                                                      A 10               A 166 ± 19/104 ± 6           A 152 ± 16/94 ± 9[d](#tf1-4){ref-type="table-fn"}    A 56                                                                   
  [@b62]                                                  db, p/8[e](#tf1-5){ref-type="table-fn"}         325/31--74                                  L 10               L 155 ± 11/99 ± 3            L 141 ± 13/87 ± 7[f](#tf1-6){ref-type="table-fn"}    L≡NG≡F                                              L≡NG≡F             L≡NG \< F[g](#tf1-7){ref-type="table-fn"}
                                                                                                                                                      NG 30              NG 155 ± 12/99 ± 3           NG 142 ± 10/86 ± 7[f](#tf1-6){ref-type="table-fn"}                                                                          
                                                                                                                                                      F 10               F 155 ± 12/99 ± 3            F 138 ± 10/85 ± 7[f](#tf1-6){ref-type="table-fn"}                                                                           
  [@b54]                                                  db, p/8[e](#tf1-5){ref-type="table-fn"}         130/18--70                                  L 10               L 163 ± 12/101 ± 5           L 151 ± 13/91 ± 9[h](#tf1-8){ref-type="table-fn"}    L 58 (51)                                           L≡NS               L≡NS
                                                                                                                                                      NS 40              NS 163 ± 14/101 ± 4          NS 151 ± 14/91 ± 8[h](#tf1-8){ref-type="table-fn"}   NS 63 (53)                                                             
  [@b27]                                                  db, p/48[e](#tf1-5){ref-type="table-fn"}        60/30--65                                   L 10               L 159 ± 11/101 ± 6           L 137/85[a](#tf1-1){ref-type="table-fn"}             NR                                                  L≡NG               NR[i](#tf1-9){ref-type="table-fn"}
                                                                                                                                                      NG 30              NG 159 ± 10/101 ± 5          NG 21/15[a](#tf1-1){ref-type="table-fn"}                                                                                    
  Fogari et al 2000a                                      db, p/12[e](#tf1-5){ref-type="table-fn"}        60/36--70                                   L 10               L 163 ± 5/98 ± 4             L 144 ± 5/86 ± 4[a](#tf1-1){ref-type="table-fn"}     NR                                                  L≡NG               L \< NG (ankle edema)[j](#tf1-10){ref-type="table-fn"}
                                                                                                                                                      NG 30              NG 162 ± 6/97 ± 4            NG 144 ± 5/86 ± 3[a](#tf1-1){ref-type="table-fn"}                                                                           
  *Comparison with other antihypertensive drug classes*                                                                                                                                                                                                                                                                           
  Morisco et al 1997                                      db, p/8[e](#tf1-5){ref-type="table-fn"}         217/18--70                                  L 10               L 157 ± 11/100 ± 3           L 145 ± 12/90 ± 8[d](#tf1-4){ref-type="table-fn"}    L 71 (65)                                           L≡AT               L≡AT
                                                                                                                                                      AT 50              AT 157 ± 11/100 ± 4          AT 142 ± 13/88 ± 7[d](#tf1-4){ref-type="table-fn"}   AT 78 (76)                                                             
  [@b66]                                                  db, p/12[e](#tf1-5){ref-type="table-fn"}        115/18--80                                  L 10               L 161 ± 10/100 ± 3           L 147 ± 10/89 ± 7[d](#tf1-4){ref-type="table-fn"}    L 75 (81)                                           L≡C                L≡C
                                                                                                                                                      C 50               C 159 ± 10/100 ± 3           C 148 ± 11/91 ± 7[d](#tf1-4){ref-type="table-fn"}    C 73 (74)                                                              
  [@b51]                                                  db, p/24[e](#tf1-5){ref-type="table-fn"}        52/18--70                                   L 10               L 159 ± 13/105 ± 5           L 143 ± 7/92 ± 7[d](#tf1-4){ref-type="table-fn"}     L 65 (54)                                           L≡H                L \< H (lipid changes)
                                                                                                                                                      H 12.5             H 158 ± 14/103 ± 5           H 146 ± 10/93 ± 7[d](#tf1-4){ref-type="table-fn"}    H 58 (54)                                                              
  [@b36]                                                  db, p/16[e](#tf1-5){ref-type="table-fn"}        562/18--75                                  L 10               L 163 ± 15/101 ± 5           L 148 ± 16/88 ± 7                                    L ≈ 80 (71) (16w)                                   L≡LO               L≡LO
                                                                                                                                                      LO 50              LO 162 ± 13/101 ± 5          LO 144 ± 15/88 ± 8                                   LO ≈ 80 (65) (16w)                                                     
  [@b67]                                                  NR/16                                           20/53 ± 9                                   L 10               L 165 ± 8/102 ± 2            L 151 ± 9/97 ± 4[k](#tf1-11){ref-type="table-fn"}    L NR (20) (8w)                                      L≡T                NR[l](#tf1-12){ref-type="table-fn"}
                                                                                                                                                      T 80               T 166 ± 8/103 ± 5            T 152 ± 8/96 ± 4[k](#tf1-11){ref-type="table-fn"}    T NR (20) (8w)                                                         
  [@b4]                                                   open/32                                         338/55                                      L 10               L 162 ± 11/97 ± 9            L 135/82[m](#tf1-13){ref-type="table-fn"}            NR                                                  L≡CA               L≡CA
                                                                                                                                                      CA 16              CA 161 ± 10/96 ± 7           CA 133/82[m](#tf1-13){ref-type="table-fn"}                                                                                  
  *Comparative studies in the elderly*                                                                                                                                                                                                                                                                                            
  [@b16]                                                  db, p/24[e](#tf1-5){ref-type="table-fn"}        324/≥65                                     L 5                L 167 ± 11/98 ± 5            L 140/80[f](#tf1-6){ref-type="table-fn"}             L/NG \> LA (24w)[n](#tf1-14){ref-type="table-fn"}   L≡LA≡NG            L≡LA/NG[o](#tf1-15){ref-type="table-fn"}
                                                                                                                                                      LA 2               LA 168 ± 12/98 ± 4           LA 142/81[f](#tf1-6){ref-type="table-fn"}                                                                                   
                                                                                                                                                      NG 30              NG 167 ± 11/97 ± 4           NG 138/79[f](#tf1-6){ref-type="table-fn"}                                                                                   
  Leonetti et al 1999                                     db, p/26--104[e](#tf1-5){ref-type="table-fn"}   828/≥60                                     L 10               L 170 ± 10/97 ± 6            L 140/83[p](#tf1-16){ref-type="table-fn"}            L≡LA≡A                                              L≡LA≡A             L≡LA \< A[q](#tf1-17){ref-type="table-fn"}
                                                                                                                                                      LA 2               LA 170 ± 10/97 ± 6           LA 141/83[p](#tf1-16){ref-type="table-fn"}                                                                                  
                                                                                                                                                      A 5                A 171 ± 11/97 ± 7            A 141/82[p](#tf1-16){ref-type="table-fn"}                                                                                   

p \< 0.001 versus baseline.

p = 0.006.

57 ± 10 years in other treatment arm.

Values for first 4-week treatment period (p \< 0.01 versus baseline).

Dosages doubled after 4 weeks if unsatisfactory response (2 weeks in Cherubini et al, 8 weeks in James et al).

p \< 0.01 versus baseline.

p \< 0.05.

Values for first 4 weeks of treatment (p \< 0.001 versus baseline).

Sustained sympathetic activation with chronic NG therapy (p \< 0.05 versus baseline).

Ankle edema significantly greater with NG (p \< 0.001 versus L).

Values for first 8 weeks of treatment (p \< 0.001 versus baseline).

Neither drug affected insulin resistance.

Values for first 6 weeks of treatment.

p \< 0.001 between treatment groups in numbers of responding and normalized patients.

Incidence of adverse drug reactions was lowest for L.

Values are at 6 months (p \< 0.01 versus baseline). AT or enalapril (plus diuretic, if required) was added after 8 weeks in 22%--29% of patients with an unsatisfactory response.

Higher rates of edema, edema-related symptoms, and early edema-related discontinuation with A compared with L and LA (p \< 0.001).

**Abbreviations:** A, amlodipine; AT, atenolol; BP, blood pressure; co, crossover; C, captopril; CA, candesartan; DBP, diastolic BP; db, double blind; H, hydrochlorothiazide; LA, lacidipine; L, lercanidipine; LO, losartan; NE, norepinephrine; NG, nifedipine gastrointestinal therapeutic system; NR, not reported; NS, nifedipine slow-release formulation; p, parallel; sb, single blind; SBP, systolic BP; T, telmisartan.

Efficacy in specific populations
--------------------------------

### Elderly patients

Lercanidipine is effective in elderly patients with mild-to-moderate hypertension. In a double-blind, placebo-controlled study of 144 elderly patients with hypertension (aged 60--85 years), lercanidipine 10 mg/day for 4 weeks reduced systolic and diastolic blood pressure to a greater extent than placebo (15 vs 7 mmHg and 10 vs 6 mmHg, respectively, p \< 0.01 for diastolic blood pressure) and increased the response rate (59% vs 38%, p \< 0.05) ([@b50]). In an open study of 756 patients, lercanidipine (10--20 mg/day for 8 weeks) reduced blood pressure to a similar extent in patients under and over 65 years ([@b55]). Reports of 3 open studies in patients at least 60 years old show that lercanidipine produces significant reductions of systolic, diastolic, and pulse pressure in this patient population ([@b13]; [@b44]; [@b61]).

Two large controlled studies showed that lercanidipine (5--10 mg/day or 10--20 mg/day) is as effective as lacidipine (2--4 mg/day), amlodipine (5--10 mg/day), or nifedipine GITS (30--60 mg/day) at lowering blood pressure in elderly patients with hypertension ([Table 1](#tbl1){ref-type="table"}) ([@b39]; [@b16]). In elderly patients with ISH, lercanidipine was more effective than placebo in terms of reduction of systolic blood pressure and number of patients responding or being normalized after 4 and 8 weeks of therapy (p \< 0.001 for all comparisons) ([@b6]). A similar well designed study in 290 patients with ISH found that lercanidipine (10 mg/day) and lacidipine (2 mg/day) were equivalent at reducing systolic blood pressure (24 versus 22 mmHg after 16 weeks) ([@b47]).

### Concomitant diseases

Several large-scale uncontrolled trials have shown that lercanidipine is effective in antihypertensive patients with concomitant diseases or risk factors. The ELYPSE study of lercanidipine in daily clinical practice comprised 9059 patients with mild-to-moderate hypertension and a range of additional risk factors such as obesity, hypercholesterolemia, smoking, and diabetes mellitus ([@b9]). The authors found that 3 months of treatment with lercanidipine was effective at reducing blood pressure across this broad range of patients. Similar findings were achieved in an observational 6-week study of 32 345 patients with mild-to-moderate hypertension and concomitant diseases such as lipid disorders, diabetes mellitus, coronary heart disease, and heart failure ([@b45]). An open study in 3175 hypertensive patients with various levels of cardiovascular risk found that lercanidipine was effective across all risk levels and appeared most effective in those with the highest risk ([@b8]). A further study in 2793 patients with hypertension who were also overweight showed lercanidipine efficacy is not adversely affected by this cardiovascular risk factor ([@b7]).

Lercanidipine monotherapy (10 or 20 mg/day) was also effective in a randomized double-blind study of 40 patients with hypertension and type 2 diabetes mellitus where it did not adversely affect glucose homeostasis ([@b75]). In a smaller open study in 34 similar patients, lercanidipine (10 mg/day) replaced β-blocker therapy in patients not controlled by combination of an ACE inhibitor and β-blocker, and significantly reduced mean arterial pressure and glycosylated hemoglobin which the authors attributed to decreased vascular resistance ([@b19]). Lercanidipine (10 mg/day) was found to produce a similar reduction in insulin resistance to telmisartan (80 mg/day) in a study of 20 patients with mild-to-moderate hypertension ([@b67]).

Lercanidipine (10 mg/day) did not adversely affect proteinuria in 42 patients with hypertension and diabetes who also had chronic renal failure when added to existing but inadequate therapy with an ACE inhibitor or angiotensin receptor blocker ([@b59]). Significantly, lercanidipine (10--20 mg/day over 9--12 months) was found to reduce blood pressure and reduce albumin excretion rate in a randomized, double-blind study of 277 patients with hypertension, diabetes, and microalbuminuria, producing a similar result to ramipril 5--10 mg/day ([@b21]). Most recently, lercanidipine (10 mg/day for 6 months) produced significant reductions in blood pressure, cholesterol, and triglyceride levels in 203 patients with hypertension and chronic renal failure, previously treated with ACE inhibitors or angiotensin receptor blockers. Furthermore, creatinine clearance was increased and proteinuria reduced adding further support to a role for lercanidipine in improving renal function ([@b60]).

### Following unsuccessful therapies or used in combination therapy

Two daily practice studies of lercanidipine included a large proportion of patients (66% and 69%) who had achieved a poor response or complained of adverse events when treated with other antihypertensive medications ([@b9]; [@b68]). In one of the studies, lercanidipine was given as monotherapy and produced significant blood pressure reduction over 3 months (p \< 0.001 versus baseline) with 64% achieving diastolic blood pressure lower than 90 mmHg ([@b9]). In the other study, it was equally effective when given as monotherapy or combined with other antihypertensive agents ([@b68]).

The efficacy of lercanidipine as add-on therapy has been shown in several open studies. In a study of 756 hypertensive patients, lercanidipine (10 mg/day) reduced blood pressure over 8 weeks as monotherapy or as combination therapy ([@b55]). Lercanidipine (10mg/day) is also effective when combined with ACE inhibitor or angiotensin receptor blocker therapy ([@b30]; [@b59]) and reduces blood pressure more than β-blocker plus ACE inhibitor combination therapy ([@b19]) in patients with diabetes mellitus and hypertension. In one study of 80 patients with hypertension resistant to monotherapy (including β-blockers, ACE inhibitors, or diuretics), lercanidipine (10 mg/day) or nitrendipine (10 mg/day) as add-on therapy produced significant decreases in blood pressure after 4 weeks and approximately 90% of patients were normalized in each group at 12 weeks ([@b57]).

Several other antihypertensive drugs have been successfully added to lercanidipine monotherapy. For example, combining lercanidipine with hydrochlorothiazide or telmisartan increased the rate of blood pressure normalization in patients where an unsatisfactory response to lercanidipine monotherapy was observed after either 4 or 8 weeks therapy ([@b54]; [@b67]). Similarly, lercanidipine plus candesartan therapy was found to be effective in 70% of patients who had not responded to 6 weeks of monotherapy with either drug ([@b4]).

Tolerability and patient compliance
-----------------------------------

A pooled analysis of 20 randomized, double-blind studies shows that adverse events were reported by 11.8% of 1317 lercanidipine-treated patients (10--20 mg/day) versus 7.0% in those who received placebo (227) for 1--52 weeks of treatment ([@b38]). Most adverse events occurred within the first 4 weeks of treatment and there were only slight differences from placebo when lercanidipine was given at its starting dose of 10 mg/day and then titrated to higher dosages. Adverse events with lercanidipine 10 mg/day included flushing (1.1% vs 0.4% for placebo), ankle edema 0.9% vs 1.3%), palpitations (0.6% vs 0.4%), headache (2.3% vs 1.3%), vertigo (0.4% vs 0.4%), and asthenia (0.4% vs 0.4%). The incidence of adverse events in elderly patients was 5.70%, which compared well with younger patients (6.60%) ([@b38]). An analysis of 14 placebo-controlled, double-blind trials (1850 patients with hypertension or stable angina treated for up to 18 weeks) confirmed that adverse events with lercanidipine (10--20 mg/day) are generally mild-to-moderate ([@b34]). Headache (5.6%), edema (2.4%, tachycardia (2.1%), flushing (2.0%), palpitations (1.7%), rhinitis (1.3%), and hypokalemia (1.2%) were the most frequently-reported treatment-emergent adverse events compared with headache (3.8%), hypokalemia (1.3%), and hyperuricemia (1.1%) with placebo.

Lercanidipine was well tolerated in all of the uncontrolled studies and in the controlled studies reported in [Table 1](#tbl1){ref-type="table"}. It produced no significant heart rate changes, while most adverse events were the result of vasodilatation early in treatment. Lercanidipine also compared well against amlodipine, felodipine, and nifedipine GITS ([Table 1](#tbl1){ref-type="table"}). Specifically, objective assessments have shown that lercanidipine produces less pedal edema than nifedipine GITS ([@b25]) and amlodipine ([Figure 2](#fig2){ref-type="fig"}) ([@b39]; [@b40]; [@b53]). The incidence of edema was also low in a general practice study of 8981 hypertensive patients who received lercanidipine combined with other antihypertensive agents (the incidence was lowest when lercanidipine was given with an ACE inhibitor) ([@b43]). The comparative tolerability of lercanidipine and other DHPs were investigated in an open study of 125 patients with hypertension and drug-specific adverse events. Lercanidipine (10--20 mg/day for 4 weeks) produced significant reductions in edema, flushing, headache, rash, and dizziness when it was switched from previous treatment with amlodipine, nifedipine GITS, felodipine, or nitrendipine (p \< 0.001) ([@b11]). Weir has commented that the 2.4% incidence of edema found with lercanidipine (10--20 mg/day) in a pooled analysis ([@b34]) contrasts well with incidences of 6%--29% found in studies of other DHPs ([@b34]; [@b76]).

![Amlodipine produces significantly more leg edema than lercanidipine after 2 weeks therapy in patients with mild to moderate hypertension (p = 0.006) ([@b53]).](vhrm0103-173-f2){#fig2}

Reported withdrawal rates with lercanidipine are low or similar to placebo ([@b6]; [@b9]; [@b68]). This is most probably related to its good tolerability -- withdrawals due to edema are less with lercanidipine than with amlodipine ([@b39]; [@b40]) and nifedipine GITS ([@b62]).

Patient support/disease management programs
===========================================

Official organizations have recently re-issued their guidelines on hypertension ([@b17]; [@b24]; [@b78]) and readers may consult these documents to update on diagnosis, evaluation, and non-pharmacological approaches to treatment. There is general agreement for drug intervention if systolic/diastolic blood pressures are greater than 140/90 mmHg (high risk groups may be treated at lower levels) and that first-line therapy may comprise any of the 5 major drug classes ([@b72]), largely because of their equivalent blood pressure lowering ability that has the greatest benefit ([@b24]).

Diuretics may be favored for their low cost and extent of outcome data ([@b20]; [@b2]; [@b17]); even though the results of the ALLHAT study do not support their prevailing role in terms of prevention of coronary events or increased survival ([@b2]). Moreover, diuretics have adverse metabolic effects and may affect male sexual function, which may be important limitations for their chronic use ([@b72]). Assuming equal blood pressure lowering efficacy across all drug classes, the decision on which drug to prescribe may come down to its likely adverse events and the individual patient\'s risk profile (eg, age, target organ damage, concomitant diseases). With regard to calcium antagonists, these are metabolically neutral and may be favored across a wide range of patients with hypertension, including the elderly, those with ISH, angina pectoris, diabetes mellitus, peripheral vascular disease, carotid atherosclerosis, and during pregnancy ([@b24]).

Combination therapy is appropriate in more than half of patients with hypertension ([@b72]), and calcium antagonists may be combined with any of the other 4 drug classes ([@b18]). Combination therapy is most often required in elderly patients and those with diabetes ([@b18]; [@b1]); therefore, calcium antagonists offer a reliable choice in these patients and in others with concomitant cardiovascular risks. Third generation agents such as lercanidipine circumvent the problems faced with other calcium antagonists, such as uneven therapeutic effect and reflex sympathetic and vasodilator adverse effects ([@b37]), and this may improve patient compliance ([@b76]). [Figure 3](#fig3){ref-type="fig"} provides a clinical summary of lercanidipine based on its intrinsic properties, clinical trial results and applicability to latest guidelines.

![Clinical summary of lercanidipine in hypertension. All features and comments are derived from referenced information in the text. **Abbreviations:** ACE, angiotensin converting enzyme; AEs, adverse events; DHP, dihydropyridine; ISH, isolated systolic hypertension.](vhrm0103-173-f3){#fig3}

Conclusion
==========

Lercanidipine exhibits a slow onset of action, which helps to avoid reflex tachycardia, and produces an even and sustained reduction in blood pressure. Preclinical and clinical findings suggest lercanidipine may have protective effects on the kidneys, cardiovascular system, and target organs. The antihypertensive action of lercanidipine is equivalent to many other antihypertensive agents, and it is equally effective in young and old patients and in the presence of other risk factors, including patients with renal dysfunction and/or type 2 diabetes. It is suitable for use as monotherapy or in combination with other agents, in line with current treatment guidelines. Lercanidipine is well tolerated in all age groups and DHP-associated adverse effects occur primarily in the first 4 weeks of treatment. The incidence of pedal edema and subsequent withdrawals has been found to be lower with lercanidipine than with amlodipine or nifedipine GITs. The favorable efficacy and safety profile of lercanidipine makes it a flexible choice for antihypertensive treatment across a broad range of patients.
